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ABSTRACT: Chronic renal failure is the primary cause of secondary hyperparathyroidism (SHPT). 
Patients with mineral metabolism disorders commonly present with low serum calcium levels, hyper-
phosphatemia, and calcitriol deficiency. In normal renal function subjects, parathyroid cells have a low
turnover and rarely undergo mitoses. In uremic conditions, however, parathyroid glands become hyper-
plasic and leave quiescence. During the last ten years, new molecular mechanisms have been investigat-
ed to better understand the pathogenesis of SHPT: the emerging role of the Calcium Sensing Receptor
(CaSR); the importance of the parathyroid expression of the Vitamin D receptor (VDR); the growing evi-
dence on the central role of  the Fibroblast Growth Factor 23 (FGF-23). In contrast, the discovery of a
parathyroid phosphate sensor or receptor has yet to be made. (Int J Artif Organs 2009; 32: 75-80)
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INTRODUCTION
High phosphate (P), low calcium (Ca), and vitamin D
deficiency represent the classical “triad” of the pathogen-
esis of secondary hyperparathyroidism (SHPT) in renal in-
sufficiency, in which the down-regulation of the parathy-
roid Vitamin D Receptor (VDR) and the Calcium Sensing
Receptor (CaSR) is a critical step (1). Unfortunately, thus
far no data have supported the existence of a parathyroid
P receptor/sensor. Disturbances in mineral and bone me-
tabolism have traditionally been termed “renal osteodys-
trophy” and have been classified based on bone biopsy.
Recently, however, KDIGO (Kidney Disease: Improving
Global Outcomes) developed an internationally accept-
able definition for renal osteodystrophy that should be
used exclusively to define alterations in bone morphology
associated with chronic kidney disease (CKD) (2). The
term CKD-Mineral and Bone Disorder (CKD-MBD) can be
used to describe bone and mineral metabolism abnor-
malities and/or ectopic calcification. 
During the last decade, a new view of the molecular
mechanisms of P homeostasis and SHPT pathogenesis
has been opened up with the Fibroblast Growth Factor
23 (FGF-23) as a novel player in the field (3). Increased
serum FGF-23 levels induce hypophosphatemia, calcitriol
suppression, and hyperparathyroidism. In contrast, low
FGF-23 is associated with high serum P levels, increased
calcitriol levels, and hypoparathyroidism. Extensive re-
search into several FGF-23 actions is still required (4). 
The role of calcium
The Ca content in a healthy adult body is 1,000-2,000
grams (25,000-50,000 mmol). In particular, only less than
2% of Ca is present in the extracellular fluid (ECF), while
>98% is part of the mineral component of bone. The Ca
of the mineral phase at the surface of the crystals is in
equilibrium with ECF Ca, even if only a minor fraction of
the total pool (0.5%) is really exchangeable. Under nor-
mal conditions, both ECF Ca concentration and body Ca
content are maintained at fixed values (5). Furthermore,
the Ca in ECF is critical for different functions, and Ca
ions inside the cell play a variety of cellular functions as
well. Most intracellular Ca is found in insoluble complex-
es. In addition, intracellular Ca levels are very low
(0.1mmol/L). The gradient between intracellular and plas-
ma free Ca levels is constantly regulated, playing a criti-
cal role for the functional regulation of the single cell. 
The normal plasma levels of Ca in healthy adults are in
a range from 8.8 to 10.4 mg/dL (from 2.2 to 2.6 mmol/L).
Plasma Ca is present in three forms: a) free ions; b) ions
bound to plasmatic proteins; c) diffusible complexes. Im-
portantly, free Ca ion concentrations might have a strong
Review
76
Mineral metabolism alterations in CKD
influence on many cellular functions, subject to tight con-
trol from the parathyroid hormone (PTH) and vitamin D
(1,25(OH)2D3) (6). Because most Ca ions are bound to 
albumin, plasmatic protein concentration is a very impor-
tant factor when the Ca ion concentration is investigated.
The pH of plasma influences the percent of protein-
bound Ca (7). In particular, to distinguish the ionized Ca
from the Ca protein-bound fractions, the K/DOQI guide-
lines state that total Ca levels have to be adjusted for
serum albumin concentration in order to better describe
the free Ca (8). Usually, the following formula is used: 
Corrected Ca (mg/dL, mmol/L) = Total Ca 
(mg/dL, mmol/L) + 0.02 x [40 – Serum Albumin (g/L)]
Extracellular Ca activates the extracellular CaSR, which
is present in different tissues, such as the PT glands, thy-
roid, intestine, kidney, bone, bone marrow, brain, skin,
lung, pancreas, and heart. Once CaSR is activated by
Ca, it couples to a complex array of intracellular signal
transduction cascades (7). Low serum Ca levels decrease
the activation and the expression of the CaSR, a plasma
membrane G-protein coupled molecule that allows PT
cells to sense Ca ions in the extracellular fluid, thus
greatly promoting PTH synthesis and secretion (9). In
contrast, hypercalcemia activates the CaSR, rapidly sup-
pressing SHPT. Recent evidence suggests that signaling
through the CaSR plays an important role on PT hyper-
plasia (10). Moreover, Ca-dependent signaling through
the CaSR may prevent PT hyperplasia even in tissues
that are non-responsive to vitamin D (11). Clearly, serum
Ca levels could also indirectly regulate PTH levels
through a feedback of 1,25(OH)2D on the PT glands. In
SHPT, PT CaSR expression is reduced, but either vitamin
D treatment or low phosphate intake are able to prevent
PT CaSR content.
Further support for the pathophysiological relevance of
changes in the expression of PT Transforming Growth
Factor alpha (TGFα and, its receptor, Epidermal Growth
Factor Receptor (EGFR) in controlling proliferative activity
came from studies which evaluated the expression of
these 2 proteins after the suppression of PT hyperplasia
by high-Ca intake or its further enhancement by low di-
etary Ca. A diet high in Ca controlled PT hyperplasia in
5/6 nephrectomized rats, decreasing PT cell growth and
the expression of both TGFα and EGFR (12). In contrast
low-Ca intake induces PT hyperplasia, preventing the in-
creases in TGFα and EGFR in the PT glands.
The role of phosphate
Since phosphate (P) is involved in many cellular
processes, it is a key component not only of bone tis-
sue, but also of many other tissues in healthy adult
subjects. The total body amount of P in a healthy adult
is about 1,000 grams (32 moL), 850 grams of which is
usually stored in the bone tissue (13). 
In fasting plasma, most of the P is present as inor-
ganic orthophosphate in concentrations from 2.8 to 4.0
mg/dL (0.9 to 2.3 mmol/L). Contrary to Ca, approxi-
mately 50% of which is bound, only about 12% of the
P is bound to plasmatic proteins. A low P intake pro-
motes a reduction in renal P excretion, preventing hy-
pophosphatemia. Clearly, renal tubular cells retain the
ability to increase P tubular transport, with a variability
among different portions of proximal tubules. Hy-
pophosphatemia stimulates 25(OH)D-1α-hydroxylase
critically modulated by renal tubular P fluxes (14). Con-
versely, hyperphosphatemia and increased renal tubu-
lar fluxes result in reduced P reabsorption, increased
clearance of P, and suppressed activity of 25(OH)D-1α-
hydro-xylase.
The kidney is the major organ in charge of controlling
P losses. P filtered through the glomerulus is reab-
sorbed to a large degree in the proximal tubule, result-
ing only in a 10% to15% excretion of the filtered load.
Physiologically, the proximal tubular reabsorption in-
creases if the filtered P load decreases. In contrast, the
P clearance increases and renal tubular reabsorption
increases if the filtered P load increases (15). Further-
more, P is a key regulatory factor of PT function. In-
deed, elevated serum P levels induce SHPT through
both direct mechanisms (inhibition of 1,25(OH)2D3 pro-
duction) and indirect ones (subsequent reduction of Ca
levels) (16). 
Hyperphosphatemia due to decreased glomerular fil-
tration rate is an important factor in the pathogenesis
of SHPT (17-18). P may also regulate PT function at
post-transcriptional level, as it improves PTH mRNA
stability (19). In contrast to the mitogenic effects of hy-
perphosphatemia, dietary P restriction appears to
counteract the proliferative signals induced by uremia,
thus preventing PT cell replication and the increase in
PT gland size (20). 
Recently, the opposing effects of high and low di-
etary P on PT hyperplasia have been demonstrated in
5/6 nephrectomized rats (21). A diet high in P worsens
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PT hyperplasia induced by uremia by enhancing PT ex-
pression of the growth factor, TGFα. Moreover, the
rapid return of PT TGFα expression to normal levels by
P restriction may suggest that low P counteracts ure-
mia-induced PT cell growth by preventing a PT TGFα
increase (21). Similar to the changes in TGFα expres-
sion, a diet high in P increased PT EGFR content to
levels above normal, while P restriction reduced PT
EGFR content (21).  
In addition, administration of highly specific EGFR-tyro-
sine kinase inhibitors (TKI), which block downstream sig-
naling from TGFα-activated EGFR, completely prevented
high P- and low Ca-induced PT cell growth (22). More im-
portantly, the suppression of signals downstream from
TGFα binding to EGFR with EGFR-TKI treatment also re-
vealed that TGFα self-upregulation in the PT glands is a
main determinant of hyperplastic growth; and that en-
hanced TGFα- activation of EGFR mediates the reduction
in PT vitamin D receptor levels, thereby causing resis-
tance to both the antiproliferative and PTH-suppressive
properties of calcitriol therapy (23).
Very recent studies (24) examined the role of activa-
tor protein 2alpha (AP2), an inducer of TGFα gene tran-
scription, in the upregulation of PT TGFα in SHPT. Both
in rats and in humans, SHPT PT AP2 expression
strongly correlated with TGFα levels and with the rate
of PT cell hyperplasia. Therefore, increased AP2 ex-
pression and transcriptional activity at the TGFα pro-
moter determine the severity of the growth driven by
PT TGFα self-upregulation in SHPT (24).
The role of vitamin D
Vitamin D is not a “vitamin”, it is a hormone. Classical-
ly, the metabolic control for activation of vitamin D is reg-
ulated by the liver and kidneys, while the target tissues
for vitamin D are the bone and the gut. Ca, P, PTH, and
other peptides regulate renal vitamin D handling. 
1,25-dihydroxycholecalciferol (1,25(OH)2D3), is the
active metabolite of vitamin D, although its serum con-
centration does not correlate with vitamin D stores. It
has been demonstrated that 1,25(OH)2D3 promotes ac-
tive and passive intestinal absorption of Ca and P,
and consequently bone mineralization. Conversely,
1,25(OH)2D3 suppresses PTH synthesis and PT cell
proliferation through a genomic activity (25). The ge-
nomic effect of 1,25(OH)2D3 is modulated by specific
cytosolic receptors for vitamin D (VDR) in target cells.
VDR forms a heterodimer with the retinoid X receptor
that enables the complex 1,25(OH)2D3-VDR to bind
with high affinity to the vitamin D response element
(VDRE) on the transcription promoters of vitamin D-
sensitive genes. VDR has been detected in vitamin D-
sensitive tissues (bone, intestine, kidney and parathy-
roid glands) and even in tissues where vitamin D acti-
vity is still unclear (myocardium, brain, pancreas and
testis). In addition to the genomic effect, a rapid non-
genomic effect of 1,25(OH)2D3 was found in intestinal
cells (14). PT VDR content is reduced in SHPT and vi-
tamin D therapy prevents PT cell growth by inducing
VDRs re-expression.  
In uremic rats, 1,25(OH)2D3 suppresses uremia-indu-
ced PT hyperplasia both in vitro (26) and in vivo (27).
Naveh-Many et al (28) showed that PTH mRNA was
much higher in PT glands from vitamin D-deficient nor-
mocalcemic rats than in controls, and that in vitamin D-
deficient hypocalcemic rats the upregulation of PTH
mRNA was even more pronounced. Moreover, many
studies have been conducted to assess whether sup-
plementation with vitamin D sterols can prevent or
ameliorate SHPT in CKD. In the early-uremia rat model
(7 days of renal failure), 1,25(OH)2D3 and the less hy-
percalcemic vitamin D analog 1,25-dihydroxy-19-
norvitamin D2 (19-norD2) controlled both serum PTH le-
vels and PT hyperplasia similarly to what is described
with phosphate restriction (21). The suppression of ure-
mic rat PT cell growth by vitamin D treatment can be
partially accounted for by the increased expression of
p21. Furthermore, studies in patients with secondary
HPT suggest an important role for increased p21 ex-
pression in PT growth arrest (27). 
The efficacy of either 1,25(OH)2D3 or 19-norD2 in arre-
sting PT hyperplasia and PT gland enlargement was
associated with prevention of TGFα and EGFR expres-
sion in the PT glands (29). Since the TGFα activation of
its receptor induces both TGFα and EGFR gene ex-
pression, it is also possible that 1,25(OH)2D3 inhibition
of EGFR activation mediates the suppressive effects of
the sterol on TGFα and EGFR expression (30).
In CKD pat ients the inabi l i ty to synthesize
1,25(OH)2D3 is sustained by decreased 1α-hydroxyla-
tion of 25(OH)D in tubular cells and occurs prior to the
increase in PTH secretion (31). Serum concentrations
of 1,25(OH)2D3 start to decrease at values of creatinine
clearance near 70 ml/min. Therefore, patients are pre-
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disposed to SHPT even in the early phases of CKD
(32). Because vitamin D sensitizes the PT gland to Ca,
it is possible that vitamin D deficiency in early CKD
may contribute to the development of SHPT, even in
the absence of overt hypocalcemia. 
The role of the fibroblast growth factor 23
(FGF-23)
Different hormonal mechanisms have been proposed
to understand the P homeostasis regulation, even if the
knowledge of this complex system remains incomplete.
PTH effectively reduces renal P resorption, which
counteracts hyperphosphatemia in CKD, and increases
renal calcitriol synthesis, leading to enhanced gastro-
intestinal P absorption and also increasing P renal re-
sorption. In the last 5 years, new factors have been in-
vestigated in the physiology of P homeostasis and in
the pathogenesis of hyperphosphatemia in CKD. In this
sense, the discovery of the Fibroblast Growth Factor
23 (FGF23) certainly represents a major milestone (4). 
Parathyroid glands are a target tissue for FGF23 (33). In
fact, FGF23 acts on PT glands both directly, reducing
PTH synthesis, and indirectly, suppressing 1-alpha-
hydroxylase. Over-production of FGF23 in subjects with
normal renal function induces hypophosphatemia, low
plasma 1,25(OH)2D3 levels, high serum PTH concentra-
tion, and severe bone demineralization (34, 35). In con-
trast, the decline of renal function in CKD patients is as-
sociated with a progressive augmentation of circulating
FGF23 concentration, which can be due to serum P ac-
cumulation and/or the decrease of the renal clearance of
FGF23 (36, 37). Once on dialysis therapy, serum FGF23
levels are markedly increased and positively correlated
with serum P levels (38). In addition, in dialysis patients,
high serum FGF23 concentration seems to predict the
occurrence of refractory SHPT as reported by several
groups (39, 40). Furthermore, a very recent study by
Gutierrez et al (3) showed that increased FGF23 levels
seem to be independently associated with mortality
among patients who are beginning HD treatment.
CONCLUSIONS
In summary, the hyperphosphatemia associated with
CKD most likely triggers FGF23 production to promote
renal P excretion, reflected by the severely elevated
FGF23 levels in CKD patients. However, given the his-
tory of protein hormone assays in patients with renal
failure, these findings should be interpreted with cau-
tion, as even “intact” hormone levels may not accurate-
ly reflect true physiology in renal disease.
In the clinic, increased knowledge of the alterations
from mineral metabolism disorders in chronic kidney
disease (CKD) may be used to improve diagnostics and
target selection for future metabolism treatments.
Therefore, the discovery of FGF23 is a major novelty in
our understanding of the pathogenesis of P handling
and SHPT in renal disease.
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